Related references
Note: Only part of the references are listed.Canavanine augments proapoptotic effects of arginine deprivation in cultured human cancer cells
Bozhena O. Vynnytska et al.
ANTI-CANCER DRUGS (2011)
Hepatocellular carcinoma: a global view
Ju Dong Yang et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2010)
Upregulation Effect of Ginsenosides on Glucocorticoid Receptor in Rat Liver
C. Binbin et al.
HORMONE AND METABOLIC RESEARCH (2009)
Arginine deprivation as a targeted therapy for cancer
L. Feun et al.
CURRENT PHARMACEUTICAL DESIGN (2008)
Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion
Paul Ning-Man Cheng et al.
CANCER RESEARCH (2007)
In vivo loss of expression of argininosuccinate synthetase in malignant pleural mesothelioma is a biomarker for susceptibility to arginine depletion
Peter W. Szlosarek et al.
CLINICAL CANCER RESEARCH (2006)
Role of polyamines in arginine-dependent colon carcinogenesis in ApcmMin/+ mice
Hagit F. Yerushalmi et al.
MOLECULAR CARCINOGENESIS (2006)
The role of NO synthases in arginine-dependent small intestinal and colonic carcinogenesis
HF Yerushalmi et al.
MOLECULAR CARCINOGENESIS (2006)
Pegylated arginine deiminase treatment of patients with metastatic melanoma: Results from phase I and II studies
PA Ascierto et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Updated treatment approach to hepatocellular carcinoma
JM Llovet
JOURNAL OF GASTROENTEROLOGY (2005)
Incidence and distribution of argininosuccinate synthetase deficiency in human cancers - A method for identifying cancers sensitive to arginine deprivation
BJ Dillon et al.
CANCER (2004)
Pegylated arginine deiminase treatment of patients with unresectable hepatocellular carcinoma: Results from phase I/II studies
F Izzo et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)